Flanked by Secretary of Health and Human Services Robert F. Kennedy Jr. and other leaders of the free world, President Trump announced on Tuesday a new <a href="https://www.dailywire.com/news/i-think-weve-found-an-answer-to-autism-what-to-know-about-trumps-major-announcement?author=Amanda+Prestigiacomo&amp;category=undefined&amp;elementPosition=105&amp;row=3&amp;rowHeadline=Latest+News&amp;rowType=Vertical+Carousel&amp;title=%E2%80%98I+Think+We%E2%80%99ve+Found+An+Answer+To+Autism%E2%80%99%3A+What+To+Know+About+Trump%E2%80%99s+Major+Announcement">investigation</a> into a potential link between a popular pain medication and autism.
During the briefing, the president pointed out that the Amish are a good example of a people with <a href="https://www.dailywire.com/news/potential-cause-treatment-of-autism-revealed-by-trump-rfk-jr?author=Amanda+Prestigiacomo&amp;category=News&amp;elementPosition=5&amp;row=0&amp;rowType=Vertical+List&amp;title=Potential+Cause%2C+Treatment+Of+Autism+Revealed+By+Trump%2C+RFK+Jr.">essentially</a> no autism.
What’s so special about the Amish? That’s easy: clean living and a high tolerance for pain. Plus, the Amish have never even heard of acetaminophen.
Underneath those broad-brimmed straw hats, plain shirts, and suspenders, however, lies a rugged, hard-working people with smooth skin and wavy hair. Amish men may have rough hands from doing rough work, but their muscular upper arms are notoriously smooth. World famous.
And who doesn&#8217;t want to be like the Amish?
Thanks to <a href="https://www.jeremysrazors.com/collections/bestselling-essentials/products/all-day-set?selling_plan=3028484309">Jeremy’s Hair &amp; Body Bundle</a>, your hair and skin can also look and feel like the Amish.
<a href="https://www.jeremysrazors.com/collections/bestselling-essentials/products/all-day-set?selling_plan=3028484309"><img loading="lazy" decoding="async" class="size-large wp-image-976453 aligncenter" src="https://dw-wp-production.imgix.net/2025/09/JR-Hair-Body-Bundle-dark-4x5-1-461x576.jpg" alt="" width="461" height="576" srcset="https://dw-wp-production.imgix.net/2025/09/JR-Hair-Body-Bundle-dark-4x5-1-461x576.jpg 461w, https://dw-wp-production.imgix.net/2025/09/JR-Hair-Body-Bundle-dark-4x5-1-240x300.jpg 240w, https://dw-wp-production.imgix.net/2025/09/JR-Hair-Body-Bundle-dark-4x5-1-768x960.jpg 768w, https://dw-wp-production.imgix.net/2025/09/JR-Hair-Body-Bundle-dark-4x5-1.jpg 1230w" sizes=" (max-width: 461px) 100vw, 461px" /></a>
Check out Jeremy’s Charcoal Body Wash, Shampoo, and Conditioner with Tea Tree, Argan Oil, &amp; Peppermint. Your hair will feel soft, and your soul refreshed.
So when the leftists shout at you about toxic masculinity while you walk back to your rig at the gun range, just remember there’s nothing toxic about using <a href="https://www.jeremysrazors.com/collections/bestselling-essentials/products/all-day-set?selling_plan=3028484309">Jeremy’s Hair &amp; Body Bundle</a>. There’s also nothing toxic about living like the Amish either: home-grown meat and potatoes all the way.
Jeremy’s bath and body products are all about freedom, just like you. They’re paraben-free, sulfate-free, and even woke-free.
Former guest host of The Oprah Winfrey Show and current Administrator for the Centers for Medicare &amp; Medicaid Services, Dr. Mehmet Oz, also had something to say about taking acetaminophen.
“Make sure there’s an important reason to take it. Don’t take it willy-nilly,” said Dr. Oz.
<div id="attachment_976455" style="width: 875px" class="wp-caption aligncenter"><img loading="lazy" decoding="async" aria-describedby="caption-attachment-976455" class="size-large wp-image-976455" src="https://dw-wp-production.imgix.net/2025/09/dea60e29-a11e-4e96-8a5e-3a6f3ffdaef8-865x576.jpg" alt="US President Donald Trump, left, and Mehmet Oz, administrator of the Centers for Medicare &amp; Medicaid Services, in the Roosevelt Room of the White House in Washington, DC, US, on Monday, Sept. 22, 2025. Trump said his administration was linking acetaminophen, the active ingredient in Tylenol, to autism and urging pregnant women to largely avoid the medication. Photographer: Francis Chung/Politico/Bloomberg via Getty Images" width="865" height="576" srcset="https://dw-wp-production.imgix.net/2025/09/dea60e29-a11e-4e96-8a5e-3a6f3ffdaef8-865x576.jpg 865w, https://dw-wp-production.imgix.net/2025/09/dea60e29-a11e-4e96-8a5e-3a6f3ffdaef8-300x200.jpg 300w, https://dw-wp-production.imgix.net/2025/09/dea60e29-a11e-4e96-8a5e-3a6f3ffdaef8-768x512.jpg 768w, https://dw-wp-production.imgix.net/2025/09/dea60e29-a11e-4e96-8a5e-3a6f3ffdaef8.jpg 1024w" sizes=" (max-width: 865px) 100vw, 865px" />Francis Chung/Politico/Bloomberg via Getty Images</div>
Dr. Oz, of course, does not have to tell the Amish not to do anything willy-nilly. The &#8220;Plain People&#8221; are among the most disciplined subcultures on the continent. Have you ever seen a willy-nilly Amish barn? We didn’t think so.
The president ended the briefing by telling the crowd that acetaminophen does cause harm.
To which Big Pharma quickly responded by saying, “Does not.”
To which Trump replied, saying, “Does too.”
Big Pharma: “Does not.”
Trump: “Does too.”
Big Pharma: “Does not.”
Trump: “Does too.”
The exchange went on for so long that the Legacy Media were forced to turn off their cameras and break for dinner before an agreement could be reached. Thankfully, the Amish in attendance had already prepared a hearty spread of meat and potatoes for all to enjoy.
The good news is, when it comes to quality shampoos and lotions that are good for your skin, you don’t have to wait for government officials to agree. 
<a href="https://www.jeremysrazors.com/">Jeremy’s</a> has the products that will make your skin and hair feel great again.

f6f34234-bcb3-448d-983d-96a16866283f

HHS Explores Link Between The Amish And Smooth Skin And Wavy Hair

Big Pharma

Daily Wire Shop

Department of Health and Human Services

Humor

Jeremy's

Satire

Drugmaker Bristol Myers Squibb is set to release a new schizophrenia treatment in the United Kingdom for the same price it’s listed for in the United States, a decision that will certainly please those in the White House who have fought to get Americans the same prices offered overseas.
The announcement, made by Bristol on Monday, follows a push from President Donald Trump for U.S. drugmakers to lower prescription drugs for Americans to the greatest extent possible. Bristol’s approach to the United Kingdom market aligns with the White House’s strategy to secure lower drug prices in the United States.
The pharmaceutical company has never before brought its price for a drug to parity across the United States and the United Kingdom. Adam Lenkowsky, chief commercialization officer at Bristol, said that the drug company is prepared to pull its drug, Cobenfy, from the European nation&#8217;s market if the relevant government authorities do not agree to the price listed in the United States, at $1,850 a month.
“Our intention is to work with NICE and NHS to make this medicine available, but we are prepared to make the difficult decision to walk away if they cannot better recognize the value our medicine brings to patients and society,” Lenkowsky said in a statement.
“We agree with the Trump Administration that other countries need to pay their fair share,” he added.
Cobenfy has not yet been approved for sale in the United Kingdom. Bristol plans to file for approval in the coming weeks and expects to receive approval sometime next year, according to the <a href="https://www.ft.com/content/0913ee5f-1631-4e1b-8bd8-99ce2c9dd64f">Financial Times</a>.
Last year, the research group RAND <a href="https://www.rand.org/news/press/2024/02/01.html">found</a> that Americans pay significantly more for prescription drugs than other countries. The research pegged the inflated price at 2.78 times what is charged in other countries.
The Trump administration is determined to end that trend, and has pointed to drug manufacturers.
“The United States has less than five percent of the world’s population and yet funds around three quarters of global pharmaceutical profits,” a May 12 White House <a href="https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/">executive order</a> on drug prices says. “This egregious imbalance is orchestrated through a purposeful scheme in which drug manufacturers deeply discount their products to access foreign markets, and subsidize that decrease through enormously high prices in the United States.”
The order aims to pressure drugmakers to push for parity between prices for its drugs in the United States and elsewhere in the world. The president last week said that other countries have treated Americans unfairly when it comes to drug prices.
“For years, we&#8217;ve been paying for a pill $100 and they&#8217;re paying $10,” the president said on Fox News last week. Trump suggested he intends to pressure other countries into raising drug prices to offset the costs of making new drugs for Americans.
“The drug companies agree that I&#8217;m right, and the countries, if they don’t agree, I’ll use tariffs to get them to agree,” Trump said. “We&#8217;re going to be reducing drug costs over the next year, year and a half by not 50% or 60%, by 1,000% … You&#8217;re talking about a monumental change in health care that&#8217;s going to affect Medicare, Medicaid, even Social Security.”
<blockquote class="twitter-tweet">
.<a href="https://twitter.com/POTUS?ref_src=twsrc%5Etfw">@POTUS</a>: &#8220;For years, we&#8217;ve been paying sometimes for a pill, $100, and [other countries] are paying $10&#8230; We&#8217;re going to be reducing drug costs over the next year, year and a half&#8230; You&#8217;re talking about a monumental change in healthcare.&#8221; <a href="https://t.co/Pxnj8vU1hc">pic.twitter.com/Pxnj8vU1hc</a>
— Rapid Response 47 (@RapidResponse47) <a href="https://twitter.com/RapidResponse47/status/1968758480476528710?ref_src=twsrc%5Etfw">September 18, 2025</a></blockquote>

UK Hosts President Trump And First Lady Melania Trump For State Visit – Day Three

Trump Push Pays Off: Pharma Giant Says Brits Must Pay Same Price As Americans For New Drug

Donald Trump

Health

Pharmaceuticals

United Kingdom

United States

World

The U.S. Food and Drug Administration (FDA) announced on Tuesday evening that it&#8217;s cracking down on deceptive pharmaceutical ads, issuing thousands of warning letters and about 100 cease-and-desist notifications.
“For far too long, the FDA has permitted misleading drug advertisements, distorting the doctor-patient relationship and creating increased demand for medications regardless of clinical appropriateness,” FDA Commissioner Dr. Marty Makary said in a statement. “Drug companies spend up to 25% of their budget on advertising. Those billions of dollars would be better spent on lowering drug prices for everyday Americans.”
A press release from the agency said current law requires pharma ads to &#8220;present a fair balance between a product’s risks and benefits; avoid exaggerating benefits; not create a misleading overall impression; properly disclose financial relationships; and include information regarding major side effects and contraindications.&#8221;
That rule, which the FDA did not adequately enforce during the Biden years, will be &#8220;aggressively&#8221; enforced now, the release says. Additionally, the FDA is closing the “adequate provision” loophole created in 1997, which companies have used to &#8220;conceal critical safety risks in broadcast and digital ads, fueling inappropriate drug use and eroding public trust.&#8221;
Television ads are not the only promotional content being scrutinized and regulated. Social media posts, which often feature an influencer talking up the drug, rarely mention &#8220;potential harms,&#8221; or they fail to disclose that the influencers are being paid.
&#8220;[W]hile 100% of pharmaceutical social media posts highlight drug benefits, only 33% mention potential harms,&#8221; the FDA said, citing a 2024 review in the Journal of Pharmaceutical Health Services Research. &#8220;Moreover, 88% of advertisements for top-selling drugs are posted by individuals and organizations that fail to adhere to the FDA fair balance guidelines.&#8221;
In the thousands of letters sent to drug companies, the FDA warns, &#8220;You are hereby directed to remove any noncompliant advertising and bring all promotional communications into compliance.&#8221;
&#8220;This notice also serves to demand compliance with the [Federal Food, Drug, and Cosmetic] Act and FDA implementing regulations and requires companies to remove any and all DTC (direct-to-consumer) prescription drug advertising that violates the law,&#8221; the letter adds.
Robert F. Kennedy Jr. &#8212; the head of Health and Human Services (HHS), which oversees the FDA &#8212; has long been a critic of Big Pharma ads. He said in a statement issued Tuesday that &#8220;pharmaceutical ads hooked this country on prescription drugs.&#8221;
&#8220;We will shut down that pipeline of deception and require drug companies to disclose all critical safety facts in their advertising,&#8221; he continued. &#8220;Only radical transparency will break the cycle of overmedicalization that drives America’s chronic disease epidemic.”
While Kennedy was running for president in 2024, before he endorsed President Donald Trump, he said he would &#8220;issue an executive order banning pharmaceutical advertising on television.&#8221;
&#8220;We are one of only two countries in the world that allow pharmaceutical companies to advertise directly to consumers on television,&#8221; RFK Jr. said on X in 2024. &#8220;Not surprisingly, Americans consume more pharmaceutical products than anyone else on the planet.&#8221;

Great American Farmers Market 2025

Trump FDA Announces Major Crackdown On ‘Misleading’ Pharma Ads

Politics

Prescription Drugs

Robert F. Kennedy Jr.

Woman holding contraceptive pill

How Big Pharma Covered Up The Dark Truth About Birth Control

Birth Control

COVID

Matt Walsh

Opinion

Pfizer

Psychology

Santa Barbara

Vaccines

Violent Crime

Monopolies have been rigging the system for decades. They cozy up to Washington, throw cash around, hire armies of lobbyists, and manipulate rules so that everyday Americans always lose.
Thankfully, President Trump isn’t playing by their rules. He’s standing up for Main Street, not corporate boardrooms.
We first saw this with Big Tech. Mark Zuckerberg <a href="https://www.nytimes.com/2025/04/02/technology/mark-zuckerberg-trump-meta-antitrust.html">thought</a> he could cut a favorable deal to get Facebook off the hook, possibly even counting on Trump to back him. Instead, the Trump administration <a href="https://www.reuters.com/sustainability/boards-policy-regulation/facebook-privacy-practices-focus-8-billion-trial-targeting-zuckerberg-2025-07-16/">allowed</a> the case to go to trial, and Zuckerberg found himself sweating it out on the witness stand. 
Google attempted a similar stunt, <a href="https://www.cnbc.com/2025/04/21/google-argues-doj-breakup-could-hurt-us-economy-in-battle-with-china.html">claiming</a> national security would be at risk if it faced a breakup. Trump’s DOJ wasn’t buying it. 
 
“You know what is dangerous?” Antitrust chief Gail Slater <a href="https://nypost.com/2025/04/30/business/google-ceo-sundar-pichai-testifies-extraordinary-doj-remedies-would-cause-many-unintended-consequences/">asked</a> outside the courthouse. “The threat Google presents to our freedom of speech, to our freedom of thought, to free American digital markets.” That case has now <a href="https://www.breitbart.com/tech/2025/08/20/google-will-soon-learn-its-fate-as-judge-prepares-to-reveal-antitrust-remedies/">reached</a> the remedies stage, and for the first time since AT&amp;T in the 1980s, we could see a Big Tech monopoly actually broken apart. That’s how monopolies should be treated.
Now Ticketmaster is running the same playbook. 
Controlling <a href="https://insights.som.yale.edu/insights/did-ticketmasters-market-dominance-fuel-the-chaos-for-swifties">80% of the market</a>, the ticket marketplace is infamous for outrageous fees and predatory practices, such as charging junk fees and allowing scalping bots to buy up most of its inventory, leaving regular fans at the mercy of price gougers. Yet now the monopoly wants Trump to think it’s the solution, not the problem. 
Ticketmaster’s owner, Live Nation, <a href="https://thehill.com/homenews/administration/5311464-ric-grenell-live-nation-board-trump-doj-ticketmaster-antitrust/">added</a> a MAGA-friendly face to its board and is now floating “reform” ideas, like capping resale prices. Such caps would <a href="https://www.whiskeyriff.com/2025/07/09/live-nation-asks-the-trump-administration-to-cap-ticket-resale-prices-which-would-conveniently-put-their-competition-out-of-business/">bankrupt</a> almost all of Ticketmaster’s rivals, leaving the company even more dominant while pretending to “fix” the market.
It’s a double scam: they make the mess, then turn around and sell the “solution” as regulation.
It’s like an arsonist showing up with a bucket of water after lighting the fire.
Fortunately, the Trump administration is not paying any attention to Ticketmaster’s desperate attempt to protect itself from the White House’s wrath. It is already <a href="https://www.claimsjournal.com/news/national/2025/03/14/329490.htm">continuing</a> the antitrust suit against Ticketmaster, and a <a href="https://www.whitehouse.gov/fact-sheets/2025/03/fact-sheet-president-donald-j-trump-will-end-price-gouging-by-middlemen-in-the-entertainment-industry/">ticketing reform plan</a> set to drop in September could put the company’s “business as usual” to an end.
<a href="https://get.dailywire.com/subscribe/plus/?utm_campaign=summer&amp;utm_content=editorialsummersale&amp;utm_medium=website&amp;utm_source=editorial">End of Summer Sale &#8211; Get 40% off New DailyWire+ Annual Memberships</a>
Big Tech and Ticketmaster aren’t alone.
In June, the Trump administration hit Mexican bank CIBanco with the <a href="https://www.foley.com/insights/publications/2025/07/fincen-new-authority-targeting-mexico-based-financial-institutions-cartel/">toughest sanctions possible</a>, accusing it of aiding the fentanyl trade. A few weeks later, CIBanco — never before a client of Washington lobbyists — <a href="https://lda.senate.gov/filings/public/filing/ab337cdd-495b-4498-a1f9-4f3b0ec83631/print/">hired</a> the MAGA-connected Rubin, Turnbull &amp; Associates. The sanctions haven’t moved, and Trump has stood firm.
Amazon has also tried its usual political maneuvering on the president. When Trump won the White House, executives <a href="https://lda.senate.gov/filings/public/filing/b22dc7d6-7900-40e4-9f3f-985bbbb32579/print/">hired</a> Brian Ballard — Trump’s former lawyer and Florida finance director — to lobby on Amazon’s behalf. They even contributed <a href="https://docquery.fec.gov/pdf/286/201704180300150286/201704180300150286.pdf">over $50,000</a> to the president’s inauguration. Did it work? No. Trump didn’t blink, and Amazon lost its effort to dodge federal antitrust charges.
Hardworking Americans are tired of being taken advantage of. Insider games, where a board seat or a lobbyist equals immunity, have gone on for too long. Trump sees it, and he’s the one president actually saying “No” loud enough for all of us to hear.
Trump is different from most politicians. He doesn’t feel he owes these corporations anything, and he isn’t inclined to give them a free pass. His administration is pushing back against any monopoly that harms consumers or breaks the law.
The bottom line? Corporate America needs to clean up its act or face the consequences. Because the Trump administration isn’t standing up for special interests, it’s standing up for everyday Americans like you and me.
* * *
Haley Kennington (@LadyKennington) is an investigative journalist and conservative commentator. She served as the Research Director &amp; Story Editor for The Daily Wire’s “2020:The Plot Against the President” and the Research/Archive Editor for “What Is a Woman?“
The views expressed in this piece are those of the author and do not necessarily represent those of The Daily Wire.

In Trump’s White House, It’s Main Street Over Monopolies

Big Tech

Corporations

President Trump

Washington D.C.

Anxious Teenage Student Sitting Examination In School Hall

The Fake ‘Mental Health’ Test Coming To Your Child’s School

Education

Health Care

Illinois

Mental Health

Public Schools

Students

President Donald Trump sent letters to drug company CEOs demanding that they lower prices.
The letters, which Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/114949049238065269">posted</a> to social media, say name-brand drug prices &#8220;are up to three times higher on average than anywhere else for identical medicines.&#8221;
&#8220;This unacceptable burden on hardworking American families ends with my Administration,&#8221; Trump said.
The letters were sent to 17 companies and are identical. They give companies 60 days to lower drug prices through most-favored-nation (MFN) pricing as explained in an executive order <a href="https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/">titled</a> &#8220;Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.&#8221;
The executive order, signed in May, orders companies to sell drugs in the United States for the same price charged in foreign countries, The Daily Wire previously <a href="https://www.dailywire.com/news/trump-signs-order-to-reduce-drug-prices-tells-rest-of-world-to-pay-up">reported</a>. The order says companies charge Americans more for drugs because &#8220;drug manufacturers deeply discount their products to access foreign markets, and subsidize that decrease through enormously high prices in the United States.&#8221;
Both the order and the letters direct companies to charge MFN prices in America.
Some of the companies that received letters include AbbVie, Eli Lilly and Company, Johnson and Johnson, Novartis, and Pfizer.
The letters tell companies to provide their &#8220;full portfolios&#8221; of drugs at MFN prices for Medicaid patients, guarantee MFN prices for new drugs, negotiate with &#8220;freeloading&#8221; nations to &#8220;return increased revenues&#8221; to American patients, and allow direct purchasing of drugs at MFN prices.
&#8220;Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices and an end to the free ride of American innovation by European and other developed nations,&#8221; Trump said in the letters.
Companies have until September 29 to implement Trump&#8217;s terms.
In May, Health and Human Services Secretary Robert F. Kennedy Jr. said other nations should chip in for research and development. He said raising prices in other nations by 20% would drastically reduce costs in the U.S.
Trump signed another executive order earlier in May to reduce the regulatory burden on the domestic production of critical medicines.
&#8220;[If] you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,&#8221; Trump said.
The other companies that received letters were Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genentech, Gilead Sciences, GSK, Merck, Novo Nordisk, Regeneron Pharmaceuticals, and Sanofi.

Johnson And Johnson Headquarters In Madrid

‘Unacceptable Burden’: Trump Gives Drug Companies 60 Days To Lower Prices

Executive

Americans have waited long enough, and now real relief from sky-high prescription drug prices is finally here. Recently, President Donald J. Trump signed a landmark Executive Order to end the decades-long injustice that has forced American families — especially Hispanic households — to pay more for lifesaving medications than almost anyone else in the world.
Hispanics, who are more likely to be uninsured or underinsured compared to other groups, are disproportionately burdened by high out-of-pocket prescription costs. In fact, according to the CDC, nearly one in four Hispanic adults report not taking prescribed medications due to cost, compared to just 13% of non-Hispanic White adults. This Executive Order directly addresses that disparity by demanding lower drug prices and making medications more affordable and accessible for millions of working families across the country.
This bold order reaffirms the President’s unwavering commitment to putting American patients first by stopping foreign free-riding, crushing the stranglehold of pharmaceutical middlemen, and bringing fairness back to a rigged system.
Under President Trump’s leadership, America is no longer the world’s piggy bank for pharmaceutical giants and socialized healthcare systems abroad. This Executive Order directs the U.S. Trade Representative and Secretary of Commerce to hold foreign nations accountable for the unfair practices that underpay for prescription drugs and undermine lifesaving drug development. In essence, Americans — who fund the bulk of pharmaceutical innovation through our taxpayer dollars and higher prices — have been subsidizing socialism abroad. No more.
For many Americans across the U.S., especially those economically impacted by high healthcare costs, this Executive Order is a game changer. Families working long hours, often balancing multiple jobs, should not have to choose between buying insulin for their children or groceries for the week. President Trump’s directive ensures that low-income patients, seniors, and working-class Americans will now have direct access to the same steep discounts that pharmaceutical companies give to patients overseas through government-negotiated prices.
That means bypassing the costly middlemen and securing medicines at “most-favored-nation” prices that reflect the best deal given to any other country in the world. If drug manufacturers refuse, the Order empowers the Secretary of Health and Human Services Robert F. Kennedy Jr. to act decisively: impose these pricing standards through regulation and take additional aggressive steps to drive costs down. This is what America First leadership looks like.
Let’s not forget: President Trump has been down this road before. In his first term, he introduced bold reforms to ensure that Medicare would no longer overpay pharmaceutical companies — specifically, by requiring that prices for Medicare-covered drugs be no higher than those paid in comparable countries. These common-sense measures were rescinded by the Biden-Harris Administration before they could take effect. The result? A so-called “victory” for Medicare that actually left American taxpayers and seniors paying an average of 78% more for prescription drugs than patients in eleven other advanced nations. That’s not a win — it’s a disgrace.
Now, in his second term, President Trump is finishing what he started. This new action builds upon earlier victories, including transparency in hospital pricing, the push for generics and biosimilars, and expanded drug importation options. These initiatives are part of a comprehensive, America First healthcare agenda focused not on enriching bureaucracy, but on empowering patients.
For those disproportionately affected by chronic conditions like diabetes, hypertension, and asthma, this move provides tangible economic relief. It ensures families can access the medicine they need to stay healthy. It means hardworking Americans can afford care without risking financial ruin. And it signals that forgotten communities are no longer overlooked — they are being heard and prioritized.
We should also be clear: this isn&#8217;t just good policy. It’s great politics. President Trump is showing the American people that he’s not afraid to stand up to entrenched interests to deliver real results. He’s not beholden to Big Pharma, nor is he willing to play nice with foreign governments who exploit our generosity while we suffer at home.
In an era where politicians too often offer empty promises and soaring rhetoric, President Trump delivers. His commitment to reforming healthcare pricing is not just about economics—it’s about justice. And make no mistake: justice is exactly what millions of Americans, especially those in underserved communities, have been demanding for years.
President Trump said it best: “Our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory.” That ends now.
This is more than an Executive Order. It’s a promise fulfilled, a burden lifted, and another bold move in President Trump’s mission to restore prosperity, fairness, and dignity to the American people.
* * *
Bobby Jindal is the former Governor of Louisiana and Chair of the Center for a Healthy America at America First Policy Institute.
Jorge Martinez is National Director for Hispanic Outreach for America First Policy Institute. He previously served as press secretary for the U.S. Department of Justice.

Trump Vows US Drug Price Cuts Of Up To 80% In Industry Blow

Trump’s Bold Move To Lower Drug Prices Puts Americans First, Not Big Pharma

Trump's Bold Move To Lower Drug Prices Puts Americans First, Not Big Pharma

Trump Administration

White House

President Donald Trump’s new <a href="https://www.cnbc.com/2025/05/12/trump-most-favored-nations-drug-price-order-what-to-know.html" target="_blank" rel="noopener">executive order</a> on prescription drug prices — which he called “one of the most consequential executive orders in our country’s history” — may well live up to the hype, but not in the way Trump intends.
Trump&#8217;s announcement of a “most favored nation” <a href="https://m.economictimes.com/news/international/global-trends/us-news-trumps-most-favored-nation-drug-pricing-policy-and-how-will-it-reduce-costs-slash-prescription-drug-prices-by-30-to-80-percent/articleshow/121109365.cms" target="_blank" rel="noopener">policy</a> means the United States government will only pay drug prices equal to the lowest paid by any developed nation. This is what Germany, France, Canada, and the United Kingdom currently do: pay less for drugs than they’re worth. In turn, the United States picks up the tab when it buys up drugs for Medicaid.
We overpay, and it’s easy to write it off as unfair freeloading by Europe, a recurring theme for the Trump administration. But this remedy will not come without its costs, and consumers will feel it down the line.
The Trump administration&#8217;s solution for drug pricing is identical to its approach to tariffs. Instead of finding leverage in a target-rich environment to coerce Europe into paying market rates, thus giving American consumers a break, they’ve decided to join the race to the bottom. Senator Bernie Sanders (I-VT) must be quietly pleased to see his socialist dream of price controls go mainstream within the MAGA coalition, even though he has <a href="https://www.newsweek.com/bernie-sanders-warning-trump-drug-pricing-executive-order-2071155" target="_blank" rel="noopener">warned</a> that Trump’s drug pricing measure would be better served by legislation.
If it was not clear to Republicans before, it should be now that free market policymaking is on the outs in the second Trump administration.
Let’s be honest about what’s happening. The White House wants to trim federal <a href="https://www.youtube.com/watch?v=4AmCRxm6P4o" target="_blank" rel="noopener">spending</a> without touching politically sensitive programs like Medicaid. To square that budgetary circle, they’ve decided to force pharmaceutical companies to sell their products to American patients at the same rate they’re sold to socialized healthcare systems abroad.
This move, unthinkable for a Republican administration two decades ago, assumes that America can have the world’s most innovative pharmaceutical sector and also ask “Big Pharma” to forgo the billions in profits they reinvest back into research and development. It’s a fantasy.
The United States is the engine of pharmaceutical innovation. Over half of all new drug patents originate here specifically because America allows firms to see a return on investment. Drug development isn’t like manufacturing sneakers or soda. It’s a high-risk, capital-intensive endeavor where failure is more common than success. A single treatment can take over a decade to develop, cost billions, and then <a href="https://med.uc.edu/depart/psychiatry/research/clinical-research/crm/trial-phases-1-2-3-defined#:~:text=Subjects%20in%20a%20Phase%20II,go%20on%20to%20Phase%20III." target="_blank" rel="noopener">never make it</a> to FDA phase III trials.
Cutting-edge treatments come to market and make the impossible suddenly possible, albeit at a premium price point. It’s true, on brand-name drugs, Americans <a href="https://aspe.hhs.gov/reports/comparing-prescription-drugs#:~:text=In%202022%2C%20U.S.%20prices%20across,adjustments%20for%20estimated%20U.S.%20rebates." target="_blank" rel="noopener">pay a lot</a> more.
However, like clockwork, generics get developed and costs for the consumer crater. Generic medications account for 91% of prescriptions in the United States. For those, we <a href="https://x.com/cremieuxrecueil/status/1921730579675934991" target="_blank" rel="noopener">pay far less</a> for those drugs than nearly any other country, something Daily Wire editor emeritus Ben Shapiro <a href="https://youtu.be/XYBuphYtp6I?si=U5SKZ4aI99bvS70w&amp;t=2662" target="_blank" rel="noopener">explained</a> this week.
If Medicaid won’t pay a fair price, pharmaceutical companies will raise prices on private insurers to compensate. That means higher premiums and out-of-pocket costs for millions of Americans who get coverage through work or on the open market.
And that’s <a href="https://www.vox.com/2021/6/7/22522479/medicaid-health-insurance-doctors-billing-research" target="_blank" rel="noopener">assuming</a> companies continue to sell to Medicaid at all.
Why isn’t Trump hammering European nations that want access to American-made drugs and have them negotiate fair, value-based deals for our biotech? It’s a crown jewel of America that global elites travel near and far to access. We should be twisting wrists abroad, not kneecapping our pharmaceutical industry.
<div>If we want lower drug costs, allowing drug approval reciprocity — as <a href="https://www.paul.senate.gov/dr-rand-paul-introduces-legislation-to-modernize-fda-prescription-drug-approvals-and-lower-drug-prices/" target="_blank" rel="noopener" data-saferedirecturl="https://www.google.com/url?q=https://www.paul.senate.gov/dr-rand-paul-introduces-legislation-to-modernize-fda-prescription-drug-approvals-and-lower-drug-prices/&amp;source=gmail&amp;ust=1747494596378000&amp;usg=AOvVaw27BgpCiXpYt8qvN3lERP1n">suggested</a> by Sen. Rand Paul — to increase competition between drug approval regulators globally would be a great start. The FDA’s approval process could also be reformed to accelerate trials and drug approval.</div>
America leads the world in medical breakthroughs for a reason. We cannot afford to surrender that leadership by copying the failures of Europe’s socialized health systems. Europe as we know it today is a warning, not a model.
Stephen Kent is the Media Director of the Consumer Choice Center.
The views expressed in this piece are those of the author and do not necessarily represent those of The Daily Wire.

TOPSHOT-US-POLITICS-HEALTH-TRUMP-KENNEDY

Undermining American Pharmaceutical Companies Won’t Make Drugs Cheaper

Europe

Executive Orders

President Trump signs an executive order to stop Big Pharma from charging Americans more than their European counterparts. Stocks surge after tariffs are slashed, as the U.S. and China announce a temporary truce in the trade war. And, Air Force 1 needs an update. Will Trump accept the offer of a $400 million “flying palace” from Qatar?
It’s Tuesday, May 13, and this is the news you need to know to start your day.
Morning Wire is available on video! You can watch today’s episode here:
<iframe loading="lazy" title="Art of the Drug Deal &amp; Tariffs Slashed!" width="500" height="281" src="https://www.youtube.com/embed/vne6uRU-n5c?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
If you’d rather listen to your news, today’s edition of the Morning Wire podcast can be heard below:
<iframe style="width: 100%; max-width: 660px; overflow: hidden; border-radius: 10px;" src="https://embed.podcasts.apple.com/us/podcast/tariffs-slashed-stocks-surge-drug-prices-cut-5-13-25/id1576594336?i=1000708297175" height="175" frameborder="0" sandbox="allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>
<h2>Trump EO To Lower Drug Prices</h2>
<div class="image"><img loading="lazy" decoding="async" class="alignnone size-full wp-image-919457" src="https://dw-wp-production.imgix.net/2025/05/SEGMENT-HEADERS.00_00_32_07.Still004.jpeg" alt="" width="640" height="360" srcset="https://dw-wp-production.imgix.net/2025/05/SEGMENT-HEADERS.00_00_32_07.Still004.jpeg 640w, https://dw-wp-production.imgix.net/2025/05/SEGMENT-HEADERS.00_00_32_07.Still004-300x169.jpeg 300w" sizes=" (max-width: 640px) 100vw, 640px" /></div>
Topline: President Trump signed what he called “one of the most consequential Executive Orders in our Country’s history” on Monday to dramatically lower the prices of prescription drugs.
Trump said his newest executive order would lower drug prices in the U.S. by up to 80% by implementing the “most favored nation” policy, cutting out industry “middlemen,” and compelling the European Union and other allies to pay for research and development of various drugs. He argued that since other nations set price controls for drugs, it’s been America that’s left taking on all these research and development costs.
“Starting today, the U.S. will no longer subsidize the healthcare of foreign countries,” Trump said. “We will no longer tolerate profiteering and price gouging from Big Pharma. But again, it was really the countries that forced Big Pharma to do things that, frankly, I’m not sure they were comfortable doing.”
The order will allow Americans to buy drugs directly from manufacturers, cutting out pharma “middlemen.” These so-called “middlemen,” pharmacy benefit managers (PBMs), work with insurance providers to negotiate prices with drug companies in exchange for including the drugs in their coverage. Critics say PBMs are not transparent and don’t have an incentive to lower drug prices for Americans. The order also sets a <a href="https://apnews.com/article/trump-prescription-drugs-prices-most-favored-nation-4c620a32ccd193b793ba1558f3fe93e0">30-day deadline</a> for HHS to work with drugmakers to reduce the costs of these prescription drugs. If a deal is not reached, a new rule will kick in that will effectively lower the drug price to what other nations are paying for them.
“The fundamental problem in healthcare is we&#8217;ve had non-competitive markets,” Dr. Marty Makary, the head of the Food and Drug Administration, <a href="https://x.com/RapidResponse47/status/1921938509826298179">said</a> on Monday. “We can do little things around the edges, or we can transform those markets to competitive markets and that&#8217;s what this executive order does today.&#8221;
Democrats, who as a general rule have opposed President Trump’s policies, have remained mostly silent on this executive order. Senator Bernie Sanders (I-VT), an independent and democratic socialist who caucuses with the Democrats, said that he agrees with Trump about the high prices of prescription drugs, but he did not back this EO, arguing that it would be blocked by the courts. Trump implemented a similar regulation for certain cancer drugs during his first term. The Biden administration, however, <a href="https://www.wsj.com/politics/policy/trump-says-he-will-sign-executive-order-aimed-at-lowering-drug-prices-2a5b9b28">abandoned</a> the regulation after a court struck it down on procedural grounds. Sanders also made it clear that he doesn&#8217;t agree that the European Union or Canada needs to pay their &#8220;fair share&#8221; – he thinks prices should be lowered for everyone.
<h2>Stock Market Soars As U.S./China Slash Tariffs</h2>
<div class="image"><img loading="lazy" decoding="async" class="alignnone size-full wp-image-919343" src="https://dw-wp-production.imgix.net/2025/05/SEGMENT-HEADERS.00_01_37_02.Still002-2.jpeg" alt="" width="640" height="360" srcset="https://dw-wp-production.imgix.net/2025/05/SEGMENT-HEADERS.00_01_37_02.Still002-2.jpeg 640w, https://dw-wp-production.imgix.net/2025/05/SEGMENT-HEADERS.00_01_37_02.Still002-2-300x169.jpeg 300w" sizes=" (max-width: 640px) 100vw, 640px" /></div>
Topline: Stocks soared Monday after the United States and China formally agreed to a temporary trade deal that will dramatically lower tariffs across the board.
After formal negotiations in Switzerland last weekend, China agreed to cut tariffs on American imports from 125% to just 10%, while the United States will cut rates from 145% to 10%. Beijing also agreed to eliminate or suspend non-tariff countermeasures against the United States, which means that their ban on rare earth mineral exports could come to an end.
&#8220;Yesterday, we achieved a total reset with China,” President Trump <a href="https://x.com/RapidResponse47/status/1921928176286020061">said</a> on Monday. “After productive talks in Geneva, both sides now agree to reduce the tariffs imposed after April 2nd to 10% for 90 days as negotiators continue on the largest structural issues.&#8221;
This deal is a stunning reversal of hostilities — ahead of last weekend’s meetings, for example, even Treasury Secretary Scott Bessent seemed to think a deal was a long way off, saying his goal was “de-escalation… not a big trade deal.”
Clearly, the Chinese were more willing to negotiate than many expected — Beijing signed on to a joint statement that referenced a “spirit of mutual opening, continued communication, cooperation, and mutual respect.” That’s quite a different message than we heard last month, when the Chinese were calling the U.S. bullies who would be made to pay. As more proof of the improvement in relations, the two sides also agreed to establish a formal process for streamlined trade talks in the future, including using a third country as a mediator.
However: The Trump administration has made clear that while it is willing to open up the flow of certain Chinese goods, it wants to break U.S. reliance on essential imports like weapons, technology, and pharmaceuticals.
“The United States will continue a strategic rebalancing in many areas that were exposed as supply chain weaknesses during COVID,” Secretary Bessent <a href="https://x.com/CookedGooseinFL/status/1921880651646611609">said</a> on Monday. “Whether it’s medicines, whether it’s semi-conductors, steel … we will continue moving towards U.S. independence or reliable supplies from allies.”
Following news of the deal, the Dow Jones Industrial Average jumped more than 1000 points, the S&amp;P 500 rose more than 3%, erasing all its losses from last month, and the NASDAQ shot up more than 4%, marking a 20% increase from its recent low in April.
<h2>&#8220;Flying Palace&#8221; To Replace Air Force One?</h2>
<div class="image"><img loading="lazy" decoding="async" class="alignnone size-full wp-image-919345" src="https://dw-wp-production.imgix.net/2025/05/SEGMENT-HEADERS.00_02_33_26.Still003.jpeg" alt="" width="640" height="360" srcset="https://dw-wp-production.imgix.net/2025/05/SEGMENT-HEADERS.00_02_33_26.Still003.jpeg 640w, https://dw-wp-production.imgix.net/2025/05/SEGMENT-HEADERS.00_02_33_26.Still003-300x169.jpeg 300w" sizes=" (max-width: 640px) 100vw, 640px" /></div>
Topline: Trump is off to the Middle East this week for what the White House promises to be a trip of dealmaking and diplomacy. But the president’s trip is off to a controversial start thanks to a story about a $400 million Qatari airplane.
On Sunday, <a href="https://abcnews.go.com/Politics/trump-administration-poised-accept-palace-sky-gift-trump/story?id=121680511">ABC News</a> reported that the Qatari royal family planned to give Trump a $400 million super luxury Boeing 747-8 jumbo jet described as a “floating palace.” The plane would reportedly be available for Trump to use in lieu of Air Force One by the end of his term, and then – according to some initial reports – transferred to his presidential library. Trump says it’s merely the Qataris helping the United States replace Air Force One, which is 40 years old, and, according to Trump, in need of some serious upgrades. Speaking to reporters before departing for the Middle East yesterday, Trump said the Qataris knew Boeing had delayed production of the new jet he wanted, and stepped in to help.
“I think that was a very nice gesture,” the president <a href="https://x.com/factpostnews/status/1921942334930907441">said</a>. &#8220;Now, I could be a stupid person and say &#8216;Oh no, we don’t want a free plane&#8217; … I would never be one to turn down that kind of an offer.”
However, not everyone sees this as just a goodwill gesture. Qatar is one of the wealthiest nations in the world, and uses its wealth to gain influence in the United States – and many, many other countries. It frequently invites politicians on luxurious, state-funded junkets to the Middle East. But that influence-buying sparks suspicion, because Qatar also uses its oil money to bankroll Hamas terrorists and Middle Eastern news powerhouse Al Jazeera. The country has also been accused of a lengthy list of human rights violations, so any collaboration with the Qataris is bound to raise some eyebrows.
Notable MAGA loyalists, including pro-Trump activist Laura Loomer, were quick to <a href="https://x.com/LauraLoomer/status/1921615017138618439">condemn</a> the decision, warning that accepting the plane was bad optics at best, and a security risk at worst. Trump, for his part, is staying on the offensive, calling accusations of conflict of interest “fake news.”
Qatar’s media attaché to the United States has been making the rounds since the ABC story broke, telling reporters that the aircraft transfer would only be used temporarily, and that nothing has been finalized yet.

MorningWire-0428-2

Morning Brief: Qatar Force One And Trump’s ‘Consequential’ Drug Price Plan

Communist China

Media

Morning Wire

Qatar

President Donald Trump on Monday morning signed an executive order to significantly reduce pharmaceutical drug prices for Americans.
The directive, Trump stressed, will bring fairness to Americans and cut out &#8220;the middlemen&#8221; to bring prices down so citizens will start to pay prices comparable to other developed nations.
&#8220;Starting today, the United States will no longer subsidize the drug prices of other countries,&#8221; the president said. &#8220;We&#8217;ve been subsidizing drug prices for the rest of the world, not just the European Union.&#8221;
By implementing a policy called &#8220;Most Favored Nation,” Trump said the U.S. is &#8220;gonna pay the lowest price there is in the world. We&#8217;re no longer paying ten times more than another country.&#8221;
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who was with Trump at a press conference on Monday morning, said that other nations, particularly those in the European Union, must chip in for research and development. Kennedy said raising their prices by just 20% would dramatically reduce costs in the United States.
Trump teased the executive order Sunday night on Truth Social, saying it would reduce prices by up to 80%.
<blockquote class="twitter-tweet">
JUST IN: PRESIDENT TRUMP&#8217;S &#8220;MOST IMPORTANT AND IMPACTFUL&#8221; TRUTH EVER ISSUED ⬇️
&#8220;I am pleased to announce that Tomorrow morning, in the White House, at 9:00 A.M., I will be signing one of the most consequential Executive Orders in our Country’s history&#8230;.&#8221; <a href="https://t.co/YfyKzked0S">pic.twitter.com/YfyKzked0S</a>
— The White House (@WhiteHouse) <a href="https://twitter.com/WhiteHouse/status/1921695676032856313?ref_src=twsrc%5Etfw">May 11, 2025</a></blockquote>
During Trump&#8217;s first term, he introduced a regulation for certain cancer drugs and others to be the same price as they were abroad. The Biden administration, however, <a href="https://www.wsj.com/politics/policy/trump-says-he-will-sign-executive-order-aimed-at-lowering-drug-prices-2a5b9b28" target="_blank" rel="noopener">abandoned</a> the regulation after a court struck it down on procedural grounds.
White House Press Secretary Karoline Leavitt discussed the order on Monday, saying online that other presidents &#8220;merely talked about addressing this problem – but President Trump is taking bold action to finally solve it and deliver a good deal for American families and seniors.&#8221;
&#8220;President Trump is signing a historic Executive Order to significantly reduce drug prices for Americans,&#8221; she posted on X. &#8220;This EO will help bypass costly middlemen and bring the prices Americans pay for prescription drugs in line with those paid by other nations.&#8221;
<blockquote class="twitter-tweet">
President Trump is signing a historic Executive Order to significantly reduce drug prices for Americans.
This EO will help bypass costly middlemen and bring the prices Americans pay for prescription drugs in line with those paid by other nations.
Other Presidents merely talked… <a href="https://t.co/KTD37JonpH">pic.twitter.com/KTD37JonpH</a>
— Karoline Leavitt (@PressSec) <a href="https://twitter.com/PressSec/status/1921907172528607564?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
White House Health Policy Adviser Calley Means, the brother of surgeon general nominee Casey Means, promoted the order online, posting on X, &#8220;The U.S. is less than 5% of the world’s population but produces 75% of worldwide pharma profits. That’s not the free market. It&#8217;s rank corporate capture.&#8221;
<blockquote class="twitter-tweet">
The U.S. is less than 5% of the world’s population but produces 75% of worldwide pharma profits.
That’s not the free market. Its rank corporate capture.
— Calley Means (@calleymeans) <a href="https://twitter.com/calleymeans/status/1921923593090248806?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
&#8220;&#8216;Price controls&#8217; would assume we have a free market in healthcare. It is not a free market when America, the largest purchaser of drugs in the world, pays 10 more for major drugs from American companies than Germany,&#8221; Means commented, responding to criticism of the order. &#8220;That’s corruption.&#8221;
<blockquote class="twitter-tweet">
“Price controls” would assume we have a free market in healthcare.
It is not a free market when America, the largest purchaser of drugs in the world, pays 10 more for major drugs from American companies than Germany.
That’s corruption.
— Calley Means (@calleymeans) <a href="https://twitter.com/calleymeans/status/1921901461132243425?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
The order follows another directive signed by Trump on May 5, which seeks to reduce the regulatory burden on the domestic production of critical medicines.
&#8220;One key area of concern is the length of time it takes to build pharmaceutical manufacturing facilities in the United States today,&#8221; the order <a href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/" target="_blank" rel="noopener">reads</a>. &#8220;New construction must navigate myriad Federal, State, and local requirements ranging from building standards and zoning restrictions to environmental protocols that together diminish the certainty needed to generate investment for large manufacturing projects.&#8221;
The order notes that estimates suggest building new pharmaceutical manufacturing plants &#8220;may take as long as 5 to 10 years, which is unacceptable from a national security standpoint.&#8221;
Within 180 days, the Administrator of the Environmental Protection Agency (EPA) will take action to &#8220;update regulations and guidance that apply to the inspection and approval of new and expanded manufacturing capacity of pharmaceutical products, active pharmaceutical ingredients, key starting materials, and associated raw materials in the United States to eliminate any duplicative or unnecessary requirements and maximize the timeliness and predictability of agency review,&#8221; the order notes.

Trump Signs Order To Reduce Drug Prices, Tells Rest Of World To Pay Up

Trump Signs Order To Dramatically Reduce Drug Prices, Tells Rest Of World To Pay Up

Business

Prices

President Donald Trump said Sunday he will sign an executive order that will reduce the cost of pharmaceuticals “almost immediately by 30% to 80%.”
Trump announced the move in a post on Truth Social. The order aims to bring “FAIRNESS TO AMERICA” by lowering drug costs in the United States while raising them throughout the rest of the world.
“Therefore, I am pleased to announce that Tomorrow morning, in the White House, at 9:00 A.M., I will be signing one of the most consequential Executive Orders in our Country’s history,” Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/114491534347862682" target="_blank" rel="noopener">said</a>.
“I will be instituting a MOST FAVORED NATION’S POLICY whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World,” he said. “Our Country will finally be treated fairly, and our citizens Healthcare Costs will be reduced by numbers never even thought of before. Additionally, on top of everything else, the United States will save TRILLIONS OF DOLLARS.”
The plan to link the cost of drugs in the United States to the cost of drugs in foreign countries comes after the president announced last month that he plans to enact “major” tariffs on pharmaceuticals.
“We’re going to tariff our pharmaceuticals,” Trump <a href="https://www.biopharmadive.com/news/trump-major-tariffs-pharmaceuticals-coming-europe/744829/" target="_blank" rel="noopener">told</a> the National Republican Congressional Committee. “And once we do that, they’re going to come rushing back into our country because we’re the big market.”
In the United States, drugs are significantly more costly than elsewhere in the world. On average, prices in the United States are ​​2.78 times higher than those seen in 33 other nations, according to a 2024 Rand Corporation <a href="https://www.rand.org/news/press/2024/02/01.html" target="_blank" rel="noopener">report</a>.
For brand name drugs, the price difference is even starker: “The gap between prices in the United States and other countries is even larger for brand-named drugs, with U.S. prices averaging 4.22 times those in comparison nations.”
Some of the contributing <a href="https://www.nytimes.com/2024/01/17/health/us-drug-prices.html">factors</a> to high drug costs in the United States are the lack of transparency in drug prices and the prevalence in foreign countries of having centralized government negotiators haggling over the cost of pharmaceuticals.

Trump Teases ‘Most Consequential Executive Order In Our Country’s History’

U.S.

Menu